New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CTRP;SWKS;RPRX;PII;LXK From The Last 14 Days
Check below for free stories on CTRP;SWKS;RPRX;PII;LXK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
08:11 EDTSWKSTriQuint chip among those in iPhone 6 Plus, iFixit reports
Subscribe for More Information
08:03 EDTSWKSInvenSense, NXP, RF Micro chips included in iPhone 6, iFixit reports
Subscribe for More Information
08:03 EDTSWKSSkyworks average iPhone content rose, says Craig-Hallum
Craig-Hallum believes that Skyworks' average content in the iPhone6/6+ rose to a little over $5.50, up from an average of around $4.80 in the iPhone 5S/5C. The firm expects Skyworks' to report beat and raise results. It keeps a $62 price target and Buy rating on the shares.
September 18, 2014
13:38 EDTRPRXRepros needed unique Androxal label even before ADCOM panel, says Ladenburg
Ladenburg said that given the FDA advisory committee's 20 to 1 vote that it believes the FDA will likely revise testosterone replacement therapy labels to restrict their use in hypogonadal patients with clear etiology. However, Ladenburg added that Repros was always going to have to establish a unique label for Androxal and the firm believes that the company's ongoing and completed trials will provide sufficient data for filing and approval by the FDA in secondary hypogonadism. The firm maintains its Buy rating and $35 price target on Repros.
12:45 EDTRPRXOn The Fly: Midday Wrap
Subscribe for More Information
11:15 EDTRPRXRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
10:52 EDTRPRXOptions with increasing implied volatility
Options with increasing implied volatility: RPRX VALE NLY AGNC
07:19 EDTRPRXRepros Therapeutics sell-off overdone, says Brean Capital
Brean Capital said the selling in Repros Therapeutics is overdone after an FDA panel voted overwhelmingly in support for a more restrictive label that limits the use of TRT drugs to only patients with classic hypogonadism. The firm feels since Androxal has not been targeting age-related hypogonadism it does not deserve to be negatively impacted by yesterday's ruling. Brean Capital maintains its Buy rating on Repros Therapeutics and $41 price target on the shares.
07:00 EDTRPRXRepros Therapeutics price target lowered to $13 from $24 at Piper Jaffray
Subscribe for More Information
06:10 EDTRPRXFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information
September 10, 2014
08:34 EDTCTRPCtrip.com confirms removal of hotel listings from Qunar, Marbridge Daily says
Subscribe for More Information
September 9, 2014
13:02 EDTLXKArtisan Partners reduces passive stake in Lexmark to 2.3% from 8.3%
Subscribe for More Information
12:28 EDTCTRPCtrip.com removed products from Qunar site, GeoInvesting says
GeoInvesting tweeted that after visiting Qunar's (QUNR) website it confirmed Ctrip.com (CTRP) has removed its hotel products from Qunar's website. Shares of Qunar are down 3% to $30.80 in midday trading.
September 8, 2014
08:31 EDTLXKLexmark announces results of Readsoft tender offer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use